Test Code LPAGF Lymphocyte Proliferation to Antigens, Blood
Reporting Name
Lymphocyte Proliferation, AntigensPerforming Laboratory
Mayo Clinic Laboratories in RochesterUseful For
Assessing T-cell function in patients on immunosuppressive therapy, including solid-organ transplant patients
Evaluating patients suspected of having impairment in cellular immunity
Evaluation of T-cell function in patients with primary immunodeficiencies, either cellular (DiGeorge syndrome, T-negative severe combined immunodeficiency [SCID], etc) or combined T- and B-cell immunodeficiencies (T- and B-negative SCID, Wiskott-Aldrich syndrome, ataxia telangiectasia, common variable immunodeficiency, among others) where T-cell function may be impaired
Evaluation of T-cell function in patients with secondary immunodeficiency, either disease related or iatrogenic
Evaluation of recovery of T-cell function and competence following bone marrow transplantation or hematopoietic stem cell transplantation
This test is not intended for assessment of maternal engraftment.
Method Name
Flow Cytometry
Ordering Guidance
This test should not be ordered for patients younger than 3 months unless there is a clinical history of candidiasis. For more information see Cautions.
Shipping Instructions
Testing performed Monday through Friday. Specimens not received by 4 p.m. Central time on Friday may be canceled.
Specimens arriving on the weekend and observed holidays may be canceled.
Collect and package specimen as close to shipping time as possible. Ship specimen overnight in an Ambient Shipping Box-Critical Specimens Only (T668) following the instructions in the box. It is recommended that specimens arrive within 24 hours of collection.
Necessary Information
1. Date and time of collection
2. The ordering healthcare professional's name and phone number are required.
Specimen Required
Supplies: Ambient Shipping Box-Critical Specimens Only (T668)
Container/Tube: Green top (sodium heparin)
Specimen Volume: 20 mL
See tables for information on recommended volume based on absolute lymphocyte count
Pediatric Volume:
<3 months: 1 mL
3-24 months: 3 mL
25 months-18 years: 5 mL
Collection Instructions: Send whole blood specimen in original tube. Do not aliquot.
Additional Information: For serial monitoring, it is recommended that specimen collection be performed at the same time of day.
Table. Blood Volume Recommendations Based on Absolute Lymphocyte Count (ALC)
Antigen only |
||
ALC x 10(9)/L |
Blood volume for minimum Candida albicans (CA) and tetanus toxoid (TT) Only |
Blood volume for full assay |
<0.5 |
>18.5 mL |
>40 mL |
0.5-1.0 |
18.5 mL |
40 mL |
1.1-1.5 |
8.5 mL |
20 mL |
1.6-2.0 |
6.0 mL |
12 mL |
2.1-3.0 |
4.5 mL |
10 mL |
3.1-4.0 |
3.0 mL |
6 mL |
4.1-5.0 |
2.5 mL |
5 mL |
>5.0 |
2.0 mL |
4 mL |
Mitogen and antigen |
||
ALC x 10(9)/L |
Blood volume for minimum of each assay |
Blood volume for full assay |
<0.5 |
>28 mL |
>60 mL |
0.5-1.0 |
28 mL |
60 mL |
1.1-1.5 |
12 mL |
30 mL |
1.6-2.0 |
8.5 mL |
20 mL |
2.1-3.0 |
6.5 mL |
15 mL |
3.1-4.0 |
4.5 mL |
10 mL |
4.1-5.0 |
3.5 mL |
8 mL |
>5.0 |
2.5 mL |
6 mL |
Specimen Type
WB Sodium HeparinSpecimen Minimum Volume
<6 years: 1 mL; 6-18 years: 2 mL; >18 years: 6 mL
Specimen Stability Information
Specimen Type | Temperature | Time | Special Container |
---|---|---|---|
WB Sodium Heparin | Ambient | 48 hours | GREEN TOP/HEP |
Reject Due To
Gross hemolysis | Reject |
Gross lipemia | Reject |
Reference Values
Viability of lymphocytes at day 0: ≥75.0%
Maximum proliferation of Candida albicans as % CD45: ≥5.7%
Maximum proliferation of Candida albicans as % CD3: ≥3.0%
Maximum proliferation of tetanus toxoid as % CD45: ≥5.2%
Maximum proliferation of tetanus toxoid as % CD3: ≥3.3%
Interpretation
Abnormal antigen stimulation test results are indicative of impaired T-cell function if T-cell counts are normal or only modestly decreased. If there is profound T-cell lymphopenia, there could be a dilution effect with underrepresentation of T cells within the peripheral blood mononuclear cell population that could result in lower T-cell proliferative responses. However, this is not a significant concern in the flow cytometry assay, since acquisition of additional cellular events during analysis can compensate for artificial reduction in proliferation due to lower T-cell counts.
In the case of antigen-specific T-cell responses to tetanus toxoid (TT), there can be absent responses due to natural waning of cellular immunity, if the interval between vaccinations has exceeded the recommended period, especially in adults. In such circumstances, it would be appropriate to measure TT-specific T-cell responses 4 to 6 weeks after a booster vaccination.
There is no absolute correlation between T-cell proliferation in vitro and a clinically significant immunodeficiency, whether primary or secondary, since T-cell proliferation in response to activation is necessary, but not sufficient, for an effective immune response. Therefore, the proliferative response to antigens can be regarded as a more sensitive, but less specific, test for the diagnosis of infection susceptibility.
No single laboratory test can identify or define impaired cellular immunity on its own.
Controls in this laboratory and most clinical laboratories are healthy adults. Since this test is used for screening and evaluating cellular immune dysfunction in infants and children, it is reasonable to question the comparability of proliferative responses between healthy infants, children, and adults. It is reasonable to expect robust T-cell-specific responses to TT in children without cellular immune compromise, as a result of repeated childhood vaccinations. The response to Candida albicans can be more variable depending on the extent of exposure and age of exposure. A comment will be provided in the report documenting the comparison of pediatric results with an adult reference range and correlation with clinical context for appropriate interpretation.
Without obtaining formal pediatric reference values, it remains a possibility that the response in infants and children can be underestimated. However, the practical challenges of generating a pediatric range for this assay necessitate comparison of pediatric data with adult reference values or controls.
Day(s) Performed
Monday through Friday
Report Available
11 to 14 daysTest Classification
This test was developed using an analyte specific reagent. Its performance characteristics were determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the US Food and Drug Administration.CPT Code Information
86353
86353 (if appropriate)
LOINC Code Information
Test ID | Test Order Name | Order LOINC Value |
---|---|---|
LPAGF | Lymphocyte Proliferation, Antigens | 69042-0 |
Result ID | Test Result Name | Result LOINC Value |
---|---|---|
32325 | Interpretation | 69052-9 |
32326 | Viab of Lymphs at Day 0 | 33193-4 |
32327 | Max Prolif of CA as % CD45 | 69014-9 |
32328 | Max Prolif of CA as % CD3 | 69015-6 |
32329 | Max Prolif of TT as % CD45 | 69016-4 |
32330 | Max Prolif of TT as % CD3 | 69029-7 |
32331 | Antigen Comment | 48767-8 |
Reflex Tests
Test ID | Reporting Name | Available Separately | Always Performed |
---|---|---|---|
AGSTM | Additional Flow Stimulant, LPAGF | No, (Bill Only) | No |
Testing Algorithm
To ensure the most reliable results, if insufficient peripheral blood mononuclear cells are isolated from the patient's sample due to low white blood cell counts or specimen volume received, selected dilutions or stimulants may not be tested at the discretion of the laboratory.
Testing with one stimulant will always be performed. When adequate specimen is available for both stimulants to be tested, the second stimulant will be evaluated at an additional charge.